KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Acquisitions & Divestments (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Change in Acquisitions & Divestments data on record, last reported at -$4.8 billion in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 59.37% year-over-year to -$4.8 billion; the TTM value through Dec 2025 reached $16.0 million, changed N/A, while the annual FY2025 figure was $16.0 million, N/A changed from the prior year.
  • Change in Acquisitions & Divestments reached -$4.8 billion in Q4 2025 per VRTX's latest filing, down from $1.3 billion in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $1.8 billion in Q2 2025 and bottomed at -$4.8 billion in Q4 2025.
  • Average Change in Acquisitions & Divestments over 5 years is $71.3 million, with a median of $129.7 million recorded in 2022.
  • Peak YoY movement for Change in Acquisitions & Divestments: surged 5395.24% in 2021, then plummeted 1023.52% in 2022.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $47.2 million in 2021, then tumbled by 1023.52% to -$435.9 million in 2022, then surged by 270.68% to $744.0 million in 2023, then crashed by 503.95% to -$3.0 billion in 2024, then tumbled by 59.37% to -$4.8 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were -$4.8 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.8 billion in Q2 2025.